BAL 3833

Drug Profile

BAL 3833

Alternative Names: BAL3833; CCT 3833

Latest Information Update: 13 Jun 2016

Price : $50

At a glance

  • Originator The Institute of Cancer Research
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Jun 2016 Pharmacodynamics data from preclinical studies in Solid tumours released by Basilea
  • 26 Apr 2016 Pharmacodynamics data from preclinical studies presented at the American Association for Cancer Research (AACR-2016)
  • 05 May 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in United Kingdom (PO) (NCT02437227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top